Analysts See $-0.67 EPS for Cellectis S.A. (CLLS) on May, 8

April 16, 2018 - By Sonya McDaniel

Cellectis S.A. (NASDAQ:CLLS) Corporate Logo

Cellectis S.A. (NASDAQ:CLLS)’s quarterly earnings will be revealed On May, 8., Faxor reports. Analysts expect change of 19.64 % or $0.11 from previous year’s $-0.56 earnings per share compared to current’s $-0.67 earnings per share. -11.84 % EPS growth is what analysts predict. $-0.76 earnings per share was revealed for last [previous quarter]. On during the last trading session the stock decreased $0.23 or 0.75%, reaching $30.42.Cellectis S.A. has 407,271 shares volume, 20.00% up from normal. CLLS is uptrending and has moved 30.21% since April 17, 2017. CLLS outperformed by 18.66% the S&P500.

Cellectis S.A. (NASDAQ:CLLS) Ratings Coverage

In total 3 analysts cover Cellectis SA (NASDAQ:CLLS). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. 67% are bullish. 3 are the (NASDAQ:CLLS)’s analyst reports since October 27, 2017 according to StockzIntelligence Inc. On Friday, October 27 the rating was maintained by Jefferies with “Buy”.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France.The firm is worth $1.24 billion. The firm operates through two divisions, Therapeutics and Plants.Currently it has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

Cellectis S.A. (NASDAQ:CLLS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.